SCHEMBL18220481

SCHEMBL18220481

COC1OC(CN=[N+]=[N-])C(C)C(C)C1OC(C)=O

nearest known ligand 0.35

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.35
THRB P10828 1/20 0.35
HSD17B10 Q99714 1/20 0.35
BCHE P06276 1/20 0.35
F10 P00742 1/20 0.34
OGA O60502 1/20 0.33
PTPN1 P18031 1/20 0.32
MMP9 P14780 1/20 0.31
MMP12 P39900 1/20 0.31
LGALS8 O00214 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15756359 1.00 CYP2D6 (0.35) CYP2D6THRBHSD17B10BCHEF10
SCHEMBL15756360 0.92 OGA (0.40) CYP2D6THRBHSD17B10OGAPTPN1
SCHEMBL19843966 0.88 OGA (0.40) CYP2D6THRBHSD17B10OGAPTPN1
SCHEMBL20173253 0.88 OGA (0.40) CYP2D6THRBHSD17B10OGAPTPN1
SCHEMBL17822790 0.86 CYP2D6 (0.45) CYP2D6THRBHSD17B10BCHEF10
SCHEMBL19714361 0.86 CYP2D6 (0.45) CYP2D6THRBHSD17B10BCHEF10
SCHEMBL17099877 0.86 CYP2D6 (0.45) CYP2D6THRBHSD17B10BCHEF10
SCHEMBL16522127 0.86 CYP2D6 (0.33) CYP2D6THRBHSD17B10OGA
SCHEMBL19587067 0.84 OGA (0.43) CYP2D6THRBHSD17B10OGAPTPN1
SCHEMBL15756357 0.84 GBA1 (0.32) CYP2D6THRBHSD17B10OGAPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 CYP2D6 4354/4885THRB 3979/4885HSD17B10 3726/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 CYP2D6 4354/4885THRB 3979/4885HSD17B10 3726/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA CYP2D6 4377/4885THRB 3870/4885HSD17B10 3737/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA CYP2D6 4377/4885THRB 3870/4885HSD17B10 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.